FY26 Appendix 4E and Annual Report

• Revenues increased by 80.0% to $3,658,573
• Net loss after tax decreased by 50.6% to $16,171,009
• Successful completion of Phase II in-vitro platelet study with USAISR
• Partnership with Vitalant Innovation Center and Hoxworth Blood Center
• A$30 million institutional placement completed at A$2.60 per share

Vitrafy Life Sciences Limited reported an 80.0% increase in revenues to $3,658,573 for the year ended 30 June 2026, with a 50.6% decrease in net loss after tax to $16,171,009. The company achieved a major milestone with the successful completion of a Phase II in-vitro platelet study with the U.S. Army Institute of Surgical Research, demonstrating the efficacy of its cryopreservation ecosystem. Vitrafy also announced strategic partnerships with Vitalant Innovation Center and Hoxworth Blood Center to address the end-of-life of legacy red blood cell cryopreservation technology. Additionally, the company completed a A$30 million institutional placement to support scaling manufacturing, U.S. commercial operations, and working capital.

Expect U.S. manufacturing capability to be established in the first half of FY2027

Vitrafy enters FY2027 with multiple pathways to revenue and adoption, focusing on commercial relationships, manufacturing ramp-up, and FDA registration.